ADVERTISEMENT
ADVERTISEMENT

Tag: SITC

Iovance Biotherapeutics to Present Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Cell Therapies Across Multiple Solid Tumors and Treatment Settings at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

Oral Presentation of Clinical Data for TIL in Combination with Pembrolizumab in Immune Checkpoint Inhibitor-Naïve Patients with Advanced Cancers Poster for LN-145 Monotherapy in Advanced, Immune Checkpoint Inhibitor-Treated Non-Small Cell Lung Cancer ...

Page 1 of 2 1 2